Latest Oncology News

Darolutamide Tablets Usher in New Standard of Care in mHSPC

Darolutamide Tablets Usher in New Standard of Care in mHSPC

August 12th 2022

OncLive Staff

Jacob Berchuck, MD, discusses the effect of the approval of darolutamide tablets on the standard of care for patients with metastatic hormone sensitive prostate cancer.

Expanded Efficacy Data Underscore Nivolumab Combinations Role as Standard of Care for ESCC

Expanded Efficacy Data Underscore Nivolumab Combinations Role as Standard of Care for ESCC

August 12th 2022

Brittany Lovely

Recent data highlight the value of the newly approved indications for nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma.

Single-Agent Pembrolizumab Maintains Survival Benefit in Sorafenib-Pretreated Advanced HCC

Single-Agent Pembrolizumab Maintains Survival Benefit in Sorafenib-Pretreated Advanced HCC

August 12th 2022

Chris Ryan

Pembrolizumab monotherapy continued to demonstrate durable antitumor activity with promising overall survival in patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib, according to updated data from cohort 1 of the phase 2 KEYNOTE-224 trial.

Panitumumab Plus mFOLFOX6 Improves Survival in RAS Wild-Type mCRC

Panitumumab Plus mFOLFOX6 Improves Survival in RAS Wild-Type mCRC

August 12th 2022

Caroline Seymour

Treatment with frontline panitumumab and mFOLFOX6 led to a significant improvement in overall survival, plus higher response rates and R0 resection rates, compared with bevacizumab and mFOLFOX6 in patients with RAS wild-type metastatic colorectal cancer.

Adagrasib Elicits Responses in KRAS G12C–Mutant NSCLC

Adagrasib Elicits Responses in KRAS G12C–Mutant NSCLC

August 12th 2022

Ashling Wahner

Joshua K. Sabari, MD, discusses the significance of adagrasib as an agent with favorable central nervous system penetration and importance of performing next-generation sequencing in all patients with non–small cell lung cancer to detect KRAS G12C mutations.

Latest Oncology Videos

All Oncology News

Targeted Agents Continue to Emerge for HER2+ GI Cancers

August 12th 2022

Ryan Scott

After HER2 was established as an actionable target in gastric cancer, its amplification has become a key biomarker of interest for other gastrointestinal cancers.

Addressing the Unique Needs of LGBTQ+ Cancer Patients

August 12th 2022

Rutgers Cancer Institute of New Jersey

Joan Hogan, DSW, LCSW, OSW-C, and Rosemarie Slirzewski, MSW, LCSW, expand on the unique needs and challenges of LGBTQ+ individuals who are faced with cancer.

Combination Therapies and HER2-Targeted Agents Signal Favorable Responses in Gastrointestinal Cancers

August 12th 2022

Ashling Wahner

Anne M. Noonan, MBBCh, discusses prominent new therapies in hepatocellular carcinoma, the benefits of immunotherapy in gastric cancer, chemotherapy developments in pancreatic cancer, and the importance of considering HER2-targeted therapy in metastatic colorectal cancer.

FDA Approves Trastuzumab Deruxtecan for HER2-Mutant NSCLC

August 11th 2022

Kristi Rosa

The FDA has granted an accelerated approval to fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic non–small cell lung cancer whose tumors have activating HER2 mutations, as detected by an FDA-approved test, and who have received previous systemic therapy.

Katz Considers the Role of Neoadjuvant Chemoradiation in Borderline Resectable Pancreatic Cancer

August 11th 2022

OncLive Staff

Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.

Tolinapant Displays Encouraging Activity and Safety in Relapsed/Refractory PTCL/CTCL

August 11th 2022

Chris Ryan

Single-agent tolinapant generated promising response rates with a manageable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma, according to data from the phase 2 ASTX660-01 trial.

FDA Grants Regular Approval to Capmatinib for METex14+ NSCLC

August 11th 2022

Kristi Rosa

The FDA has granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic non–small cell lung cancer whose tumors have a mutation leading to MET exon 14 skipping, as detected by an FDA-approved test.

Immunotherapy Combination Selection Is Driven by PD-L1 in Gastroesophageal Cancer

August 11th 2022

Ryan Scott

Andrew H. Ko, MD, discusses the multitude of treatment options for patients with gastroesophageal cancer, emerging combinations in hepatocellular carcinoma, and how HER2 expression can drive therapy decisions in colorectal cancer.

FDA Approves VENTANA MMR RxDx To Identify dMMR Solid Tumors and as Companion Diagnostic for pMMR Endometrial Cancer

August 11th 2022

Chris Ryan

The FDA has expanded its approval of the VENTANA MMR RxDx panel to identify patients with mismatch repair–deficient solid tumors and as a companion diagnostic assay to determine eligibility for pembrolizumab as a treatment for patients with mismatch repair–proficient endometrial cancer.

FDA Grants Priority Review to Elacestrant for ER+/HER2- Advanced or Metastatic Breast Cancer

August 11th 2022

Kristi Rosa

The FDA has granted priority review to a new drug application seeking the approval of elacestrant for use in patients with estrogen receptor–positive/HER2-negative advanced or metastatic breast cancer.

Montefiore Einstein Cancer Center Researchers Receive Price Family Foundation Health Equity Research Awards

August 11th 2022

Montefiore Einstein Center for Cancer Care

The National Cancer Institute-designated Montefiore Einstein Cancer Center has partnered with the Price Family Foundation to fund 8 research teams developing novel cancer therapies and improving cancer outcomes for historically marginalized communities in the Bronx.

CC-99282 Demonstrates Manageable Safety Profile, Elicits Favorable Responses in Non-Hodgkin Lymphoma

August 11th 2022

Ashling Wahner

Jean-Marie Michot, MD, discusses the methods and rationale for the CC-99282-NHL-001 study.

Dr. Beckermann on the Need for Biomarkers in Frontline RCC

August 10th 2022

Kathryn E. Beckermann, MD, PhD

Kathryn E. Beckermann, MD, PhD, discusses the need for biomarkers in frontline renal cell carcinoma.

Dr. Hamilton on Tests to Identify HER2-Low and HER2+ Breast Cancer

August 10th 2022

Erika P. Hamilton, MD

Erika P. Hamilton, MD, discusses testing used to identify patients with HER2-positive and HER2-low breast cancer.

NCCN Elevates Sacituzumab Govitecan-Hziy to Preferred Recommendations in Metastatic Breast Cancer

August 10th 2022

Jason Harris

Sacituzumab govitecan-hziy is now a category 1 preferred recommendation in triple-negative breast cancer and a category 2A preferred recommendation in HR-positive/HER2-negative disease.

See All News